menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

CAMBRIDGE, Mass. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the appointment of Derek Hicks to a newly created
Read More

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) to enter clinical study CAMBRIDGE, Mass. , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy CAMBRIDGE, Mass. , Nov. 22, 2021 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United
Read More

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics , Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , today announced the presentation of data from its
Read More

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022 Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) On track to
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its third quarter 2021 financial results
Read More

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that the U.S.
Read More

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to
Read More

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three
Read More

Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress

First data highlighting proprietary allogeneic cell engineering platform designed to overcome immune rejection for the development of therapeutic candidates to treat a variety of cancer and autoimmune diseases New data on proprietary cell engineering process utilizing lipid nanoparticle-based
Read More
RSS FEEDS
PRINT PAGE